Erich Seifritz

Director of the Clinic for Affective Disorders at the University of Zurich

Data updated

Papers

28 publications

Trials

0 clinical trials

Research Footprint

Erich Seifritz appears in 28 tracked papers (2012–2026), most studied alongside Psilocybin, Placebo and LSD, across Healthy Volunteers, Neuroimaging & Brain Measures and Depressive Disorders.

Most-cited paper: Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor (408 citations).

Frequent co-authors: Franz Vollenweider, Katrin Preller and Rafael Kraehenmann.

Background & Research

Erich Seifritz is a full professor of psychiatry and a leading expert in affective disorders. His research investigates functional brain connectivity and the neurobiology of major depression and schizophrenia. In the psychedelic field, he focuses on psilocybin-assisted therapy and its potential to enhance therapeutic outcomes when combined with psychological frameworks and mindfulness practices.

Key Impact

Prominent psychiatrist exploring the synergy between mindfulness and psilocybin for depression.

28

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

28 collaborators· click a node to visit their profile

Full network →

Compounds

PsilocybinPlaceboLSDKetamineAyahuascaDMTMDMA

Topics

Healthy VolunteersNeuroimaging & Brain MeasuresDepressive DisordersMajor Depressive Disorder (MDD)Safety & Risk ManagementTreatment-Resistant Depression (TRD)Medicinal Chemistry & Drug DevelopmentAnxiety DisordersInterpersonal Functioning & Social ConnectednessSubstance Use Disorders (SUD)Set & SettingChronic PainPTSDSuicidalityPersonality & Trait FactorsAlcohol Use Disorder (AUD)Equity and Ethics

Top Collaborators

Affiliations

Institutions, companies, and organisations Erich Seifritz is associated with.

University of Zurich

academic

Within the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.

View stakeholder →